Companies · Biotechnology

Celcuity Inc.

MINNEAPOLIS · Biotechnology

Diligence memoA one-page analyst read on Celcuity Inc. — recommendation, valuation, rhythm, risks.
$303.0M
Total raised · real
9
Rounds
1.0×
Latest step-up
Top 3%
Sector rank · raised
Recurring offerings
Latest stage · inferred · Fri Oct 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Celcuity Inc. has raised $303M over 9 rounds; too few niche peers to rank its valuation yet.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

At-risk
  • Last raise 2.7 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Recurring offering issuermedium confidence

Celcuity Inc. behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Program-like
Frequent filings and follow-ons read more like a securities offering program than discrete startup rounds.
Lifecycle
12.3 yr record
Peak capital year was 2021 with $335.0M across 7 filings.
Market position
ahead of 98% of Biotechnology peers
Capital scale is ahead of 98% of Biotechnology peers; modeled value is above 86% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Lower applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Needs review
Row-level filing totals differ from canonical totals, so amendment/superseded filtering should be checked.
What triggered this
  • 30 dated financing filings, averaging about 4 months apart.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2021: $335.0M across 7 filings.
  • Largest single filing was $130.0M on 2021-04-08.
  • Filing rows sum to $614.5M, while canonical raised total is $303.0M; likely amendments/superseded rows are mixed into the detail view.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
  • Canonical filtering should be tightened before using row-level totals for diligence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Celcuity Inc. is one of 4291 Biotechnology companies tracked from MINNEAPOLIS. By capital raised it ranks among the largest (ahead of 98% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
2
Investors (latest)
2023-10-20
First sale
Amount raised vs valuation, by year

This issuer has a dense recurring filing history, so the chart groups filings by year. Solid bars are annual reported capital reported; hatched bars show the latest modeled value est. observed in that year. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Annual capital raised · realLatest value in year · estCumulative funded · real

Dense history compressed: 30 filings shown as 7 yearly buckets. Hover a bucket for filing count, annual capital, and latest modeled value.

$0$1.3B$2.5B$3.8B$5.0B2014: 1 filing Raised $4.0M total (real) Latest modeled valuation $178M (est)20141 filings2015: 2 filings Raised $7.3M total (real) Latest modeled valuation $187M (est)20152 filings2016: 1 filing Raised $325K total (real) Latest modeled valuation $12M (est)20161 filings2017: 16 filings Raised $68M total (real) Latest modeled valuation $115M (est)201716 filings2021: 7 filings Raised $335M total (real) Latest modeled valuation $4.2B (est)20217 filings2022: 1 filing Raised $100M total (real) Latest modeled valuation $2.2B (est)20221 filings2023: 2 filings Raised $100M total (real) Latest modeled valuation $691M (est)20232 filings+$7.3M+$325K+$68M+$335M+$100M+$100MCumulative $614M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps

This looks like a recurring offering series, so a VC stage ladder would be misleading. Showing the filed offering sequence instead.

Initial offering$4.0M · 2014
Follow-on offering$2.1M · 2015
Follow-on offering$5.2M · 2015
Follow-on offering$325K · 2016
Follow-on offering$5.8M · 2017
Follow-on offering$5.9M · 2017
Follow-on offering$5.8M · 2017
Follow-on offering$5.9M · 2017
Follow-on offering$5.9M · 2017
Follow-on offering$5.9M · 2017
Follow-on offering$5.9M · 2017
Follow-on offering$5.9M · 2017
Follow-on offering$2.6M · 2017
Follow-on offering$2.6M · 2017
Follow-on offering$2.6M · 2017
Follow-on offering$2.6M · 2017
Follow-on offering$2.6M · 2017
Follow-on offering$2.6M · 2017
Follow-on offering$2.6M · 2017
Follow-on offering$2.6M · 2017
Follow-on offering$15.0M · 2021
Follow-on offering$35.0M · 2021
Follow-on offering$5.0M · 2021
Follow-on offering$35.0M · 2021

Showing first 24 of 30 filings to keep the sequence readable.

Modeled valuation trajectory
$691.3M
Base estimate est.
$226.7M
Conservative case
$1.0B
Upside case
$416.7M
Modeled post-money

This issuer files recurring offerings, so the model treats stage labels as a loose sizing heuristic, not a clean VC ladder. The estimate anchors on reported filing amounts and dates, then applies benchmark dilution, survival, and markup assumptions. Directional, not a quoted figure.

Seed · modeled $177.6M · 2014-02-282014Seed · modeled $95.5M · 2015-12-04Series A · modeled $187.1M · 2015-12-04Series A · modeled $11.7M · 2016-02-11Series A · modeled $207.9M · 2017-04-28Series A · modeled $214.4M · 2017-04-28Series A · modeled $207.9M · 2017-04-28Series A · modeled $214.4M · 2017-04-28Series A · modeled $214.4M · 2017-04-28Series A · modeled $214.4M · 2017-04-28Series A · modeled $214.4M · 2017-04-28Series A · modeled $214.4M · 2017-04-28Seed · modeled $115.2M · 2017-05-05Seed · modeled $115.3M · 2017-05-05Seed · modeled $115.3M · 2017-05-05Seed · modeled $115.3M · 2017-05-05Series A · modeled $93.9M · 2017-05-05Seed · modeled $114.9M · 2017-05-05Seed · modeled $114.9M · 2017-05-05Seed · modeled $115.3M · 2017-05-05Series A · modeled $373.9M · 2021-04-08Series B · modeled $997.9M · 2021-04-08Series A · modeled $124.6M · 2021-04-08Series B · modeled $997.9M · 2021-04-08Series A · modeled $373.9M · 2021-04-08Series C · modeled $3.1B · 2021-04-08Series D+ · modeled $4.2B · 2021-04-08Series D+ · modeled $2.2B · 2022-05-15Series C · modeled $581.4M · 2023-10-20Series D+ · modeled $691.3M · 2023-10-202023
Model inputs · modeled:benchmark-stage-stepup-v1
12%
Dilution assumption
Implied ownership sold in the financing.
68%
Survival probability
54% low · 75% high
1.39×/yr
Annual markup
1.56×/yr upside case
2.7 yr
Elapsed time used
2.7 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
4 mo
Avg between rounds
$31.4M/yr
Capital velocity
12.3 yr
On record since
2014
First round
30
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 42× above median
This company$303.0M
Sector median$7.2M
Modeled value — vs sector median (estimate, all stages) 11× above median
This company$691.3M
Sector median$64.2M

Raised more than 98% of sector peers (real $). Modeled value above 86% of peers (estimate).

Full financing history

This issuer files too frequently for VC stage labels to be meaningful, so rows are shown as initial/follow-on offerings est. instead of Pre-Seed/Seed/Series buckets.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Initial offering$4.0M2014-02-28$20.0M$177.6M85%
Follow-on offering$2.1M2015-12-04$10.8M$95.5M85%
Follow-on offering$5.2M2015-12-04$23.5M$187.1M85%
Follow-on offering$325K2016-02-11$1.5M$11.7M85%
Follow-on offering$5.8M2017-04-28$26.1M$207.9M90%
Follow-on offering$5.9M2017-04-28$27.0M$214.4M90%
Follow-on offering$5.8M2017-04-28$26.1M$207.9M90%
Follow-on offering$5.9M2017-04-28$27.0M$214.4M90%
Follow-on offering$5.9M2017-04-28$27.0M$214.4M90%
Follow-on offering$5.9M2017-04-28$27.0M$214.4M90%
Follow-on offering$5.9M2017-04-28$27.0M$214.4M90%
Follow-on offering$5.9M2017-04-28$27.0M$214.4M90%
Follow-on offering$2.6M2017-05-05$13.0M$115.2M90%
Follow-on offering$2.6M2017-05-05$13.0M$115.3M90%
Follow-on offering$2.6M2017-05-05$13.0M$115.3M90%
Follow-on offering$2.6M2017-05-05$13.0M$115.3M90%
Follow-on offering$2.6M2017-05-05$11.8M$93.9M90%
Follow-on offering$2.6M2017-05-05$12.9M$114.9M90%
Follow-on offering$2.6M2017-05-05$12.9M$114.9M90%
Follow-on offering$2.6M2017-05-05$13.0M$115.3M90%
Follow-on offering$15.0M2021-04-08$68.2M$373.9M90%
Follow-on offering$35.0M2021-04-08$194.4M$997.9M90%
Follow-on offering$5.0M2021-04-08$22.7M$124.6M90%
Follow-on offering$35.0M2021-04-08$194.4M$997.9M90%
Follow-on offering$15.0M2021-04-08$68.2M$373.9M90%
Follow-on offering$100.0M2021-04-08$666.7M$3.1B90%
Follow-on offering$130.0M2021-04-08$1.1B$4.2B90%
Follow-on offering$100.0M2022-05-15$833.3M$2.2B90%
Follow-on offering$50.0M2023-10-20$333.3M$581.4M90%
Follow-on offering$50.0M2023-10-20$416.7M$691.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Initial offering$4.0M2014-02-28
    • First recorded raise — entered as Initial offering.
    • 2 investors on this round.
  2. Follow-on offering$2.1M2015-12-04
    • Raised again after 21 mo — slower than the ~14 mo sector norm.
    • Round 1.9× smaller than the prior — bridge or down round.
    • 12 investors on this round.
  3. Follow-on offering$5.2M2015-12-04
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.4× larger than the prior — scaling up.
    • 40 investors on this round.
  4. Follow-on offering$325K2016-02-11
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 15.9× smaller than the prior — bridge or down round.
    • 6 investors on this round.
  5. Follow-on offering$5.8M2017-04-28
    • Raised 15 mo later, in step with the ~14 mo sector norm.
    • Round 17.7× larger than the prior — scaling up.
    • 39 investors on this round.
  6. Follow-on offering$5.9M2017-04-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 39 investors on this round.
  7. Follow-on offering$5.8M2017-04-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 39 investors on this round.
  8. Follow-on offering$5.9M2017-04-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 39 investors on this round.
  9. Follow-on offering$5.9M2017-04-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 39 investors on this round.
  10. Follow-on offering$5.9M2017-04-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 39 investors on this round.
  11. Follow-on offering$5.9M2017-04-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 39 investors on this round.
  12. Follow-on offering$5.9M2017-04-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 39 investors on this round.
  13. Follow-on offering$2.6M2017-05-05
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.3× smaller than the prior — bridge or down round.
    • 38 investors on this round.
  14. Follow-on offering$2.6M2017-05-05
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 38 investors on this round.
  15. Follow-on offering$2.6M2017-05-05
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 38 investors on this round.
  16. Follow-on offering$2.6M2017-05-05
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 38 investors on this round.
  17. Follow-on offering$2.6M2017-05-05
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 38 investors on this round.
  18. Follow-on offering$2.6M2017-05-05
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 38 investors on this round.
  19. Follow-on offering$2.6M2017-05-05
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 38 investors on this round.
  20. Follow-on offering$2.6M2017-05-05
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 38 investors on this round.
  21. Follow-on offering$15.0M2021-04-08
    • Raised again after 47 mo — slower than the ~14 mo sector norm.
    • Round 5.8× larger than the prior — scaling up.
    • 1 investor on this round.
  22. Follow-on offering$35.0M2021-04-08
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.3× larger than the prior — scaling up.
    • 1 investor on this round.
  23. Follow-on offering$5.0M2021-04-08
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 7.0× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  24. Follow-on offering$35.0M2021-04-08
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 7.0× larger than the prior — scaling up.
    • 1 investor on this round.
  25. Follow-on offering$15.0M2021-04-08
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.3× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  26. Follow-on offering$100.0M2021-04-08
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 6.7× larger than the prior — scaling up.
    • 2 investors on this round.
  27. Follow-on offering$130.0M2021-04-08
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.3× larger than the prior — scaling up.
    • 2 investors on this round.
  28. Follow-on offering$100.0M2022-05-15
    • Raised 13 mo later, in step with the ~14 mo sector norm.
    • Round 1.3× smaller than the prior — bridge or down round.
    • 11 investors on this round.
  29. Follow-on offering$50.0M2023-10-20
    • Raised 17 mo later, in step with the ~14 mo sector norm.
    • Round 2.0× smaller than the prior — bridge or down round.
    • 2 investors on this round.
  30. Follow-on offering$50.0M2023-10-20
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 2 investors on this round.
Intelligence
2024 ~Q1
Modeled next raise · ~4mo cadence
$50.0M
Modeled next size est.range $50.0M$80.0M
1.0×
Last step-up
$31.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
RICHARD J. NIGON3 other2017-04
Brian F. Sullivan2014-02
David F. Dalvey2015-12
Lance G. Laing2014-02
Leo G. Furcht2017-04
Leo T. Furcht2021-04
Maureen G. Cronin2017-04
Polly A. Murphy2017-04
Richard E. Buller2017-04
Vicky G. Hahne2017-04
Registry & provenance

Celcuity Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1603454
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Amicus Therapeutics, Inc.BiotechnologySeries D+$314.5M$420.4Msame sector · same stage
Dewpoint Therapeutics, Inc.BiotechnologySeries D+$286.2M$437.6Msame sector · same stage
Aligos Therapeutics, Inc.BiotechnologySeries D+$282.2M$940.0Msame sector · same stage
Surrozen, Inc./DEBiotechnologySeries D+$269.4M$657.8Msame sector · same stage
Neurona Therapeutics, IncBiotechnologySeries D+$347.5M$874.2Msame sector · same stage
Ziopharm Oncology IncBiotechnologySeries D+$368.8M$804.5Msame sector · same stage
Iambic Therapeutics, Inc.BiotechnologySeries D+$240.9M$697.2Msame sector · same stage
Alumis Inc.BiotechnologySeries D+$240.0M$432.7Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Celsense IncBiotechnologyPre-Seed$27.6M90%
Cerium Pharmaceuticals, Inc.BiotechnologySeries A$193.1M89%
Celularity Inc.BiotechnologySeries C$3.2B87%
Celularity IncBiotechnologySeries B$8.1M86%
Cernostics, Inc.BiotechnologySeries A$131.0M86%
BioCircuit Technologies, Inc.BiotechnologySeries A$111.4M86%
Cerflux, Inc.BiotechnologyPre-Seed$48.5M86%
AcuityBio CorpBiotechnologySeed$7.8M86%
Frequently asked
How much funding has Celcuity Inc. raised?
Celcuity Inc. has raised approximately $303.0M in disclosed capital across 9 recorded financing rounds, aggregated from public filings.
What is Celcuity Inc.'s estimated valuation?
Provath's modeled valuation for Celcuity Inc. is approximately $691.3M (modeled range $226.7M–$1.0B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Celcuity Inc. at?
Celcuity Inc. shows a recurring offering pattern rather than a clean VC stage progression. Its most recent recorded round closed around Fri Oct 20.
What does Celcuity Inc. do and where is it based?
Celcuity Inc. operates in the Biotechnology sector, based in MINNEAPOLIS.
Explore related

See where Celcuity Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Celcuity Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.